| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | API1, MIHB, HIAP2, RNF48, cIAP1, Hiap-2, c-IAP1 |
| WB Predicted band size | 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human BIRC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于BIRC2抗体的参考文献示例：
---
1. **文献名称**：*BIRC2/cIAP1 regulates TNF-α-mediated NF-κB signaling through antibody-based detection in colorectal cancer cells*
**作者**：Smith J, et al.
**摘要**：本研究利用特异性BIRC2抗体(克隆号：A-10)通过Western blot和免疫荧光技术，验证了BIRC2在结直肠癌细胞中调控TNF-α诱导的NF-κB信号通路的机制。结果显示，BIRC2通过泛素化修饰调控下游信号分子，其表达水平与化疗耐药性相关。
---
2. **文献名称**：*Development of a monoclonal antibody targeting BIRC2 for therapeutic intervention in melanoma*
**作者**：Chen L, et al.
**摘要**：研究团队开发了一种针对BIRC2的新型单克隆抗体(mAb-3C6)，并在黑色素瘤模型中验证其疗效。通过流式细胞术和免疫组化证实该抗体可特异性结合BIRC2.抑制其抗凋亡功能，显著增强肿瘤细胞对放疗的敏感性。
---
3. **文献名称**：*Immunohistochemical analysis of BIRC2 expression in hepatocellular carcinoma: Prognostic implications*
**作者**：Wang Y, et al.
**摘要**：利用商业化BIRC2抗体(货号：ab12345)对肝细胞癌组织样本进行免疫组化分析。研究发现，BIRC2高表达与患者总生存期缩短及肿瘤复发风险升高显著相关，提示其可作为潜在预后标志物。
---
注：以上文献信息为示例性质，实际引用时需根据具体文献核实标题、作者及内容。建议通过PubMed或Web of Science以“BIRC2 antibody”为关键词检索最新研究。
The BIRC2 antibody is a crucial tool for studying the Baculoviral IAP Repeat-Containing Protein 2 (BIRC2), also known as cellular Inhibitor of Apoptosis Protein 1 (cIAP1). BIRC2 belongs to the inhibitor of apoptosis (IAP) family, which regulates programmed cell death by suppressing caspase activity through its baculoviral IAP repeat (BIR) domains. It plays a dual role in apoptosis and NF-κB signaling, interacting with TNF receptor-associated factors (TRAFs) to modulate inflammatory responses, cell survival, and oncogenesis. Dysregulation of BIRC2 is implicated in cancers, autoimmune disorders, and chemotherapy resistance.
The BIRC2 antibody is widely used in research to detect BIRC2 expression and localization via techniques like Western blotting, immunohistochemistry, and immunofluorescence. It helps elucidate BIRC2’s mechanistic roles, such as its E3 ubiquitin ligase activity mediated by the RING domain, which promotes protein ubiquitination and degradation. Commercial BIRC2 antibodies are typically validated for specificity against human or model organism samples, though cross-reactivity with homologous proteins (e.g., BIRC3/cIAP2) requires careful experimental controls. Studies using these antibodies have revealed BIRC2’s context-dependent roles—acting as an oncogene in some cancers while exhibiting tumor-suppressive traits in others. Its therapeutic targeting, via small-molecule IAP antagonists, underscores its clinical relevance in cancer therapy.
×
